• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

探讨 RPLP0、RPLP1 和 RPLP2 表达在肺腺癌中的功能和预后价值。

Exploring the function and prognostic value of RPLP0, RPLP1 and RPLP2 expression in lung adenocarcinoma.

机构信息

Department of Pulmonary and Critical Care Medicine, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, 2800 Gongwei Road, Pudong, Shanghai, China.

Department of Outpatient, The Affiliated Hospital of Jiaxing University, The First Hospital of Jiaxing, Jiaxing, Zhejiang, China.

出版信息

J Mol Histol. 2024 Dec;55(6):1079-1091. doi: 10.1007/s10735-024-10251-z. Epub 2024 Aug 29.

DOI:10.1007/s10735-024-10251-z
PMID:39207634
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11567986/
Abstract

Lung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer (NSCLC) and is characterized by its heterogeneity and poor prognosis. The role of ribosomal proteins RPLP0, RPLP1 and RPLP2 in multiple cancers has been implicated. However, their function in LUAD and their correlation with the poor prognosis of LUAD remains elusive. In this study, we performed a comprehensive bioinformatic analysis of the impact of these ribosomal proteins on LUAD. Our findings reveal that RPLP0, RPLP1 and RPLP2 are overexpressed in LUAD, which are likely attributed to abnormal copy number variations and decreased methylation levels of their promoters. LUAD patients with high expression of RPLP0, RPLP1 or RPLP2 have worse clinical outcomes in terms of overall survival (OS), first progression (FP) and post-progression survival (PPS), indicating poor prognosis. Moreover, the expression of RPLP0, RPLP1 and RPLP2 affects immune cell infiltration in LUAD tissues. Finally, we identified multiple existing drugs that may inhibit the expression of RPLP1 and RPLP2. Collectively, our data implicate the oncogenic role of RPLP0, RPLP1 and RPLP2 in LUAD and underscore their prognostic value in LUAD patients.

摘要

肺腺癌 (LUAD) 是最常见的非小细胞肺癌 (NSCLC) 亚型，其特点是异质性和预后不良。核糖体蛋白 RPLP0、RPLP1 和 RPLP2 在多种癌症中的作用已经被涉及。然而，它们在 LUAD 中的功能及其与 LUAD 预后不良的相关性仍然难以捉摸。在这项研究中，我们对这些核糖体蛋白对 LUAD 的影响进行了全面的生物信息学分析。我们的研究结果表明，RPLP0、RPLP1 和 RPLP2 在 LUAD 中过度表达，这可能归因于异常的拷贝数变异和启动子甲基化水平降低。RPLP0、RPLP1 或 RPLP2 高表达的 LUAD 患者在总生存期 (OS)、首次进展 (FP) 和进展后生存期 (PPS) 方面的临床结局较差，表明预后不良。此外，RPLP0、RPLP1 和 RPLP2 的表达影响 LUAD 组织中的免疫细胞浸润。最后，我们确定了多种可能抑制 RPLP1 和 RPLP2 表达的现有药物。总之，我们的数据表明 RPLP0、RPLP1 和 RPLP2 在 LUAD 中具有致癌作用，并强调了它们在 LUAD 患者中的预后价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8e/11567986/8f63c967620b/10735_2024_10251_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8e/11567986/5725b1638972/10735_2024_10251_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8e/11567986/5dbaddaadcce/10735_2024_10251_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8e/11567986/43af66327ff0/10735_2024_10251_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8e/11567986/45e2ea0ba06d/10735_2024_10251_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8e/11567986/b162838f816d/10735_2024_10251_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8e/11567986/a76b845c2859/10735_2024_10251_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8e/11567986/8f63c967620b/10735_2024_10251_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8e/11567986/5725b1638972/10735_2024_10251_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8e/11567986/5dbaddaadcce/10735_2024_10251_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8e/11567986/43af66327ff0/10735_2024_10251_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8e/11567986/45e2ea0ba06d/10735_2024_10251_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8e/11567986/b162838f816d/10735_2024_10251_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8e/11567986/a76b845c2859/10735_2024_10251_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8e/11567986/8f63c967620b/10735_2024_10251_Fig7_HTML.jpg

相似文献

1
Exploring the function and prognostic value of RPLP0, RPLP1 and RPLP2 expression in lung adenocarcinoma.探讨 RPLP0、RPLP1 和 RPLP2 表达在肺腺癌中的功能和预后价值。
J Mol Histol. 2024 Dec;55(6):1079-1091. doi: 10.1007/s10735-024-10251-z. Epub 2024 Aug 29.
2
Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.SEC61G 在肺腺癌中的预后价值：基于生物信息学和体外验证的综合研究。
BMC Cancer. 2021 Nov 13;21(1):1216. doi: 10.1186/s12885-021-08957-4.
3
RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway.RPL22L1 是肺腺癌预后和免疫浸润的新型生物标志物，通过抑制 MDM2/P53 信号通路促进 LUAD 细胞的生长和转移。
Aging (Albany NY). 2024 Aug 28;16(17):12392-12413. doi: 10.18632/aging.206096.
4
Elevated Expression of Is Associated with Lung Adenocarcinoma Carcinogenesis and Poor Prognosis.高水平表达与肺腺癌的发生和不良预后相关。
DNA Cell Biol. 2020 Apr;39(4):522-532. doi: 10.1089/dna.2019.5116. Epub 2020 Feb 10.
5
High TLX1 Expression Correlates with Poor Prognosis and Immune Infiltrates in Patients with Lung Adenocarcinoma.TLX1 高表达与肺腺癌患者的不良预后和免疫浸润相关。
Curr Mol Med. 2024;24(6):801-812. doi: 10.2174/1566524023666230619123752.
6
Expression of the ribosomal proteins Rplp0, Rplp1, and Rplp2 in gynecologic tumors.核糖体蛋白 Rplp0、Rplp1 和 Rplp2 在妇科肿瘤中的表达。
Hum Pathol. 2011 Feb;42(2):194-203. doi: 10.1016/j.humpath.2010.04.020. Epub 2010 Oct 30.
7
Unveiling ficolins: diagnostic and prognostic biomarkers linked to the Tumor Microenvironment in Lung Cancer.揭示纤维胶凝蛋白：与肺癌肿瘤微环境相关的诊断和预后生物标志物。
World J Surg Oncol. 2024 Oct 10;22(1):273. doi: 10.1186/s12957-024-03558-4.
8
RPLP1 and RPLP2 Are Essential Flavivirus Host Factors That Promote Early Viral Protein Accumulation.核糖体蛋白L1和核糖体蛋白L2是促进早期病毒蛋白积累的重要黄病毒宿主因子。
J Virol. 2017 Jan 31;91(4). doi: 10.1128/JVI.01706-16. Print 2017 Feb 15.
9
Overexpression of GSDMC is a prognostic factor for predicting a poor outcome in lung adenocarcinoma.GSDMC 过表达是预测肺腺癌不良预后的一个预后因素。
Mol Med Rep. 2020 Jan;21(1):360-370. doi: 10.3892/mmr.2019.10837. Epub 2019 Nov 20.
10
Protein phosphatase 1 regulatory subunit 3G (PPP1R3G) correlates with poor prognosis and immune infiltration in lung adenocarcinoma.蛋白磷酸酶 1 调节亚基 3G（PPP1R3G）与肺腺癌的不良预后和免疫浸润相关。
Bioengineered. 2021 Dec;12(1):8336-8346. doi: 10.1080/21655979.2021.1985817.

引用本文的文献

1
High-Sensitive Spatial Proteomics for Pancreatic Cancer Progression Analysis.用于胰腺癌进展分析的高灵敏度空间蛋白质组学
bioRxiv. 2025 May 5:2025.05.01.651678. doi: 10.1101/2025.05.01.651678.
2
Targeting RPLP2 Triggers DLBCL Ferroptosis by Decreasing FXN Expression.靶向RPLP2通过降低FXN表达触发弥漫性大B细胞淋巴瘤铁死亡。
Biomedicines. 2025 May 28;13(6):1320. doi: 10.3390/biomedicines13061320.

本文引用的文献

1
Racial and socioeconomic disparities in survival among patients with metastatic non-small cell lung cancer.转移性非小细胞肺癌患者的生存中的种族和社会经济差异。
J Natl Cancer Inst. 2024 Oct 1;116(10):1697-1704. doi: 10.1093/jnci/djae118.
2
RPLP2 activates TLR4 in an autocrine manner and promotes HIF-1α-induced metabolic reprogramming in hepatocellular carcinoma.核糖体蛋白样蛋白2（RPLP2）以自分泌方式激活Toll样受体4（TLR4），并促进缺氧诱导因子-1α（HIF-1α）诱导的肝细胞癌代谢重编程。
Cell Death Discov. 2023 Dec 5;9(1):440. doi: 10.1038/s41420-023-01719-0.
3
Highly expressed RPLP2 inhibits ferroptosis to promote hepatocellular carcinoma progression and predicts poor prognosis.
高表达的核糖体蛋白L2（RPLP2）抑制铁死亡以促进肝细胞癌进展并预示不良预后。
Cancer Cell Int. 2023 Nov 18;23(1):278. doi: 10.1186/s12935-023-03140-0.
4
Unveiling the prognostic implications of RPLP1 upregulation in osteosarcoma.揭示核糖体蛋白L1前体（RPLP1）上调在骨肉瘤中的预后意义。
Am J Cancer Res. 2023 Oct 15;13(10):4822-4831. eCollection 2023.
5
DriverDBv4: a multi-omics integration database for cancer driver gene research.DriverDBv4：一个用于癌症驱动基因研究的多组学整合数据库。
Nucleic Acids Res. 2024 Jan 5;52(D1):D1246-D1252. doi: 10.1093/nar/gkad1060.
6
LRP10, PGK1 and RPLP0: Best Reference Genes in Periprostatic Adipose Tissue under Obesity and Prostate Cancer Conditions.LRP10、PGK1 和 RPLP0：肥胖和前列腺癌条件下前列腺周围脂肪组织的最佳参考基因。
Int J Mol Sci. 2023 Oct 13;24(20):15140. doi: 10.3390/ijms242015140.
7
Transcriptome-level discovery of survival-associated biomarkers and therapy targets in non-small-cell lung cancer.非小细胞肺癌中与生存相关的生物标志物和治疗靶点的转录组水平发现。
Br J Pharmacol. 2024 Feb;181(3):362-374. doi: 10.1111/bph.16257. Epub 2023 Nov 23.
8
Lung cancer risk score for ever and never smokers in China.中国的终身和从不吸烟者肺癌风险评分。
Cancer Commun (Lond). 2023 Aug;43(8):877-895. doi: 10.1002/cac2.12463. Epub 2023 Jul 6.
9
FARSB serves as a novel hypomethylated and immune cell infiltration related prognostic biomarker in hepatocellular carcinoma.FARSB 作为一种新型低甲基化且与免疫细胞浸润相关的肝癌预后生物标志物。
Aging (Albany NY). 2023 Apr 3;15(8):2937-2969. doi: 10.18632/aging.204619.
10
Ribosome biogenesis in disease: new players and therapeutic targets.核糖体生物发生在疾病中的作用：新的参与者和治疗靶点。
Signal Transduct Target Ther. 2023 Jan 9;8(1):15. doi: 10.1038/s41392-022-01285-4.